Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.

Autor: Balmaña J; Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain., Fasching PA; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany., Couch FJ; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Delaloge S; Breast Cancer Unit, Department of Cancer Medicine, Gustave Roussy, Villejuif, France., Labidi-Galy I; Department of Oncology, Geneva University Hospital, Department of Medicine, Division of Oncology, Faculty of Medicine, University of Geneva, Geneva, Switzerland., O'Shaughnessy J; Baylor University Medical Center, Texas Oncology and US Oncology, Dallas, TX, USA., Park YH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Eisen AF; Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., You B; Department of Medical Oncology, Hospices Civils of Lyon Cancer Institute, Centre for Therapeutic Investigation in Oncology and Haematology of Lyon, Lyon Sud Hospital Centre, Lyon, France.; Faculty of Medicine of Lyon Sud, Claude Bernard Lyon 1 University, Lyon, France.; GINECO-GINEGEPS, Paris, France., Bourgeois H; Medical Oncology Department, Victor Hugo Clinic-Jean Bernard Center, Le Mans, France., Gonçalves A; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.; Cancer Research Center of Marseille, Aix-Marseille University, French National Centre for Scientific Research, National Institute for Health and Medical Research, Marseille, France., Kemp Z; Breast Cancer Unit, The Royal Marsden NHS Foundation Trust, London, UK., Swampillai A; Department of Clinical Oncology, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.; Breast Cancer Now Research Unit, Guy's Hospital, King's College London, London, UK., Jankowski T; Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland., Sohn JH; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Poddubskaya E; Surgical Department N2, Clinical Center VitaMed, Moscow, Russia., Mukhametshina G; Ministry of Health of the Republic of Tatarstan, Kazan, Russia., Aksoy S; Medical Oncology Department, Hacettepe University Cancer Institute, Ankara, Turkey., Timcheva CV; Medical Oncology Department, MHAT Nadezhda, Sofia, Bulgaria., Park-Simon TW; Frauenklinik, Hannover Medical School, Hannover, Germany., Antón-Torres A; Department of Medical Oncology, Miguel Servet University Hospital and Aragon Health Research Institute, Zaragoza, Spain., John E; Statistics, AstraZeneca, Cambridge, UK., Baria K; US Medical Affairs, AstraZeneca, Gaithersburg, MD, USA., Gibson I; Global Medical Affairs, AstraZeneca, Cambridge, UK., Gelmon KA; Department of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, Canada. kgelmon@bccancer.bc.ca.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Apr; Vol. 204 (2), pp. 237-248. Date of Electronic Publication: 2023 Dec 19.

Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer.

Autor: Petrova MP; Clinic of Medical Oncology, MHAT 'Nadezhda', Sofia, Bulgaria., Eneva MI; Hospital Pharmacy 'Nadezhda' Sofia, Bulgaria., Arabadjiev JI; Department of Medical Oncology, MHAT 'Tokuda', Sofia, Bulgaria., Conev NV; Clinic of Medical Oncology, UMHAT 'St. Marina', Varna, Bulgaria., Dimitrova EG; Clinic of Medical Oncology, UMHAT 'St. Marina', Varna, Bulgaria., Koynov KD; Department of Medical Oncology, MHAT 'Serdika', Sofia, Bulgaria., Karanikolova TS; Clinic of Medical Oncology, MHAT 'Nadezhda', Sofia, Bulgaria., Valev SS; Clinic of Medical Oncology, MHAT 'Nadezhda', Sofia, Bulgaria., Gencheva RB; Clinic of Medical Oncology, MHAT 'Nadezhda', Sofia, Bulgaria., Zhbantov GA; Clinic of Medical Oncology, MHAT 'Nadezhda', Sofia, Bulgaria., Ivanova AI; Clinic of Medical Oncology, MHAT 'Nadezhda', Sofia, Bulgaria., Sarbianova II; Department of Intensive Care Unit, MHAT 'Nadezhda', Sofia, Bulgaria., Timcheva CV; Clinic of Medical Oncology, MHAT 'Nadezhda', Sofia, Bulgaria., Donev IS; Clinic of Medical Oncology, MHAT 'Nadezhda', Sofia, Bulgaria.

Publikováno v: Bioscience trends [Biosci Trends] 2020 Mar 16; Vol. 14 (1), pp. 48-55. Date of Electronic Publication: 2020 Feb 04.